Recruitment of monocytes/macrophages in different tumor microenvironments

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 2, 2013, Pages 170-179

  Lee, Heon Woo ^a   Choi, Hyun Jung ^a   Ha, Sang Jun ^a   Lee, Kyung Tae ^b   Kwon, Young Guen ^a  

^a Yonsei University   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

Macrophages; Monocytes; Receptor ligand interaction; Trafficking; Tumor microenvironment

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; L SELECTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1;

ADAPTIVE IMMUNITY; ANGIOGENESIS; B LYMPHOCYTE; CANCER INVASION; CARCINOGENESIS; HUMAN; IMMUNOREGULATION; MACROPHAGE; METASTASIS; MONOCYTE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; CELL MOVEMENT; CELL POLARITY; CHEMOKINE CCL2; CHEMOKINE CX3CL1; HUMANS; L-SELECTIN; MACROPHAGES; MONOCYTES; NEOPLASMS; RECEPTORS, CHEMOKINE; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872369042     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.12.007     Document Type: Review

References (137)

1. Jacobs P.P., Sackstein R. CD44 and HCELL: preventing hematogenous metastasis at step 1. FEBS Lett. 2011, 585:3148-3158.
2. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
3. Gordon S., Taylor P.R. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 2005, 5:953-964.
4. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
5. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
6. Shi C., Pamer E.G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 2011, 11:762-774.
7. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
8. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J. Leukoc. Biol. 2007, 81:584-592.
9. Grage-Griebenow E., Flad H.D., Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J. Leukoc. Biol. 2001, 69:11-20.
10. Weber C., Belge K.U., von Hundelshausen P., Draude G., Steppich B., Mack M., Frankenberger M., Weber K.S., Ziegler-Heitbrock H.W. Differential chemokine receptor expression and function in human monocyte subpopulations. J. Leukoc. Biol. 2000, 67:699-704.
11. Ziegler-Heitbrock H.W., Strobel M., Kieper D., Fingerle G., Schlunck T., Petersmann I., Ellwart J., Blumenstein M., Haas J.G. Differential expression of cytokines in human blood monocyte subpopulations. Blood 1992, 79:503-511.
12. Ancuta P., Liu K.Y., Misra V., Wacleche V.S., Gosselin A., Zhou X., Gabuzda D. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics 2009, 10:403.
13. Czepluch F.S., Olieslagers S., van Hulten R., Voo S.A., Waltenberger J. VEGF-A-induced chemotaxis of CD16+ monocytes is decreased secondary to lower VEGFR-1 expression. Atherosclerosis 2011, 215:331-338.
14. Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., Kayal S., Sarnacki S., Cumano A., Lauvau G., Geissmann F. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007, 317:666-670.
15. Nahrendorf M., Swirski F.K., Aikawa E., Stangenberg L., Wurdinger T., Figueiredo J.L., Libby P., Weissleder R., Pittet M.J. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J. Exp. Med. 2007, 204:3037-3047.
16. Ziegler-Heitbrock L., Ancuta P., Crowe S., Dalod M., Grau V., Hart D.N., Leenen P.J., Liu Y.J., MacPherson G., Randolph G.J., Scherberich J., Schmitz J., Shortman K., Sozzani S., Strobl H., Zembala M., Austyn J.M., Lutz M.B. Nomenclature of monocytes and dendritic cells in blood. Blood 2010, 116:e74-e80.
17. Wong K.L., Tai J.J., Wong W.C., Han H., Sem X., Yeap W.H., Kourilsky P., Wong S.C. Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets. Blood 2011, 118:e16-e31.
18. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol. Med. 2008, 14:109-119.
19. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
20. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
21. Allavena P., Garlanda C., Borrello M.G., Sica A., Mantovani A. Pathways connecting inflammation and cancer. Curr. Opin. Genet. Dev. 2008, 18:3-10.
22. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 2004, 4:71-78.
23. De Palma M., Venneri M.A., Galli R., Sergi Sergi L., Politi L.S., Sampaolesi M., Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
24. Jaiswal S., Jamieson C.H., Pang W.W., Park C.Y., Chao M.P., Majeti R., Traver D., van Rooijen N., Weissman I.L. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009, 138:271-285.
25. Oosterling S.J., van der Bij G.J., Meijer G.A., Tuk C.W., van Garderen E., van Rooijen N., Meijer S., van der Sijp J.R., Beelen R.H., van Egmond M. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J. Pathol. 2005, 207:147-155.
26. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996, 56:4625-4629.
27. Lissbrant I.F., Stattin P., Wikstrom P., Damber J.E., Egevad L., Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int. J. Oncol. 2000, 17:445-451.
28. Salvesen H.B., Akslen L.A. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int. J. Cancer 1999, 84:538-543.
29. Koukourakis M.I., Giatromanolaki A., Kakolyris S., O'Byrne K.J., Apostolikas N., Skarlatos J., Gatter K.C., Harris A.L. Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. Br. J. Cancer 1998, 77:1696-1703.
30. Zhu X.D., Zhang J.B., Zhuang P.Y., Zhu H.G., Zhang W., Xiong Y.Q., Wu W.Z., Wang L., Tang Z.Y., Sun H.C. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol. 2008, 26:2707-2716.
31. Zabuawala T., Taffany D.A., Sharma S.M., Merchant A., Adair B., Srinivasan R., Rosol T.J., Fernandez S., Huang K., Leone G., Ostrowski M.C. An ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res. 2010, 70:1323-1333.
32. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., Delaney A., Jones S.J., Iqbal J., Weisenburger D.D., Bast M.A., Rosenwald A., Muller-Hermelink H.K., Rimsza L.M., Campo E., Delabie J., Braziel R.M., Cook J.R., Tubbs R.R., Jaffe E.S., Lenz G., Connors J.M., Staudt L.M., Chan W.C., Gascoyne R.D. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N. Engl. J. Med. 2010, 362:875-885.
33. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193:727-740.
34. Oguma K., Oshima H., Aoki M., Uchio R., Naka K., Nakamura S., Hirao A., Saya H., Taketo M.M., Oshima M. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J. 2008, 27:1671-1681.
35. Kubota Y., Takubo K., Shimizu T., Ohno H., Kishi K., Shibuya M., Saya H., Suda T. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J. Exp. Med. 2009, 206:1089-1102.
36. Nowicki A., Szenajch J., Ostrowska G., Wojtowicz A., Wojtowicz K., Kruszewski A.A., Maruszynski M., Aukerman S.L., Wiktor-Jedrzejczak W. Impaired tumor growth in colony-stimulating factor 1 (CSF-1)-deficient, macrophage-deficient op/op mouse: evidence for a role of CSF-1-dependent macrophages in formation of tumor stroma. Int. J. Cancer 1996, 65:112-119.
37. Abraham D., Zins K., Sioud M., Lucas T., Schafer R., Stanley E.R., Aharinejad S. Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma. Int. J. Cancer 2010, 126:1339-1352.
38. Aharinejad S., Sioud M., Lucas T., Abraham D. Targeting stromal-cancer cell interactions with siRNAs. Methods Mol. Biol. 2009, 487:243-266.
39. MacDonald K.P., Palmer J.S., Cronau S., Seppanen E., Olver S., Raffelt N.C., Kuns R., Pettit A.R., Clouston A., Wainwright B., Branstetter D., Smith J., Paxton R.J., Cerretti D.P., Bonham L., Hill G.R., Hume D.A. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 2010, 116:3955-3963.
40. Gazzaniga S., Bravo A.I., Guglielmotti A., van Rooijen N., Maschi F., Vecchi A., Mantovani A., Mordoh J., Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Investig. Dermatol. 2007, 127:2031-2041.
41. Kimura Y.N., Watari K., Fotovati A., Hosoi F., Yasumoto K., Izumi H., Kohno K., Umezawa K., Iguchi H., Shirouzu K., Takamori S., Kuwano M., Ono M. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci. 2007, 98:2009-2018.
42. Robinson-Smith T.M., Isaacsohn I., Mercer C.A., Zhou M., Van Rooijen N., Husseinzadeh N., McFarland-Mancini M.M., Drew A.F. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007, 67:5708-5716.
43. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjallman A.H., Ballmer-Hofer K., Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br. J. Cancer 2006, 95:272-281.
44. Halin S., Rudolfsson S.H., Van Rooijen N., Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009, 11:177-186.
45. Squadrito M.L., De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol. Asp. Med. 2011, 32:123-145.
46. Movahedi K., Laoui D., Gysemans C., Baeten M., Stange G., Van den Bossche J., Mack M., Pipeleers D., In't Veld P., De Baetselier P., Van Ginderachter J.A. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res. 2010, 70:5728-5739.
47. Baronzio G.F., Galante F., Gramaglia A., Barlocco A., de Grandi S., Freitas I. Tumor microcirculation and its significance in therapy: possible role of omega-3 fatty acids as rheological modifiers. Med. Hypotheses 1998, 50:175-182.
48. Wu S.D., Ma Y.S., Fang Y., Liu L.L., Fu D., Shen X.Z. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat. Rev. 2012, 38:218-225.
49. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
50. Loeffler D.A., Keng P.C., Baggs R.B., Lord E.M. Lymphocytic infiltration and cytotoxicity under hypoxic conditions in the EMT6 mouse mammary tumor. Int. J. Cancer 1990, 45:462-467.
51. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343.
52. Lesnik P., Haskell C.A., Charo I.F. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J. Clin. Invest. 2003, 111:333-340.
53. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
54. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66:605-612.
55. Laoui D., Van Overmeire E., Movahedi K., Van den Bossche J., Schouppe E., Mommer C., Nikolaou A., Morias Y., De Baetselier P., Van Ginderachter J.A. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology 2011, 216:1192-1202.
56. Leon B., Ardavin C. Monocyte migration to inflamed skin and lymph nodes is differentially controlled by L-selectin and PSGL-1. Blood 2008, 111:3126-3130.
57. Xu H., Manivannan A., Crane I., Dawson R., Liversidge J. Critical but divergent roles for CD62L and CD44 in directing blood monocyte trafficking in vivo during inflammation. Blood 2008, 112:1166-1174.
58. Grailer J.J., Kodera M., Steeber D.A. L-selectin: role in regulating homeostasis and cutaneous inflammation. J. Dermatol. Sci. 2009, 56:141-147.
59. Mantovani A. Cancer: Inflaming metastasis. Nature 2009, 457:36-37.
60. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
61. Sakhalkar H.S., Dalal M.K., Salem A.K., Ansari R., Fu J., Kiani M.F., Kurjiaka D.T., Hanes J., Shakesheff K.M., Goetz D.J. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15895-15900.
62. Cui S., Hano H., Sakata A., Harada T., Liu T., Takai S., Ushigome S. Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. Pathol. Int. 1996, 46:751-756.
63. Tanigawa N., Lu C., Mitsui T., Miura S. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology 1997, 26:1216-1223.
64. Muller A.M., Hermanns M.I., Skrzynski C., Nesslinger M., Muller K.M., Kirkpatrick C.J. Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro. Exp. Mol. Pathol. 2002, 72:221-229.
65. Somasiri A., Nielsen J.S., Makretsov N., McCoy M.L., Prentice L., Gilks C.B., Chia S.K., Gelmon K.A., Kershaw D.B., Huntsman D.G., McNagny K.M., Roskelley C.D. Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res. 2004, 64:5068-5073.
66. Nielsen J.S., McNagny K.M. The role of podocalyxin in health and disease. J. Am. Soc. Nephrol. 2009, 20:1669-1676.
67. Martinet L., Garrido I., Filleron T., Le Guellec S., Bellard E., Fournie J.J., Rochaix P., Girard J.P. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 2011, 71:5678-5687.
68. Rosen S.D. Ligands for L-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. 2004, 22:129-156.
69. Lee S.Y., Qian C.N., Ooi A.S., Chen P., Tan V.K., Chia C.S., Hwang J.S., Teh B.T., Soo K.C. 2011 Young Surgeon's Award Winner: high endothelial venules: a novel prognostic marker in cancer metastasis and the missing link?. Ann. Acad. Med. Singapore 2012, 41:21-28.
70. Hickey M.J., Forster M., Mitchell D., Kaur J., De Caigny C., Kubes P. L-selectin facilitates emigration and extravascular locomotion of leukocytes during acute inflammatory responses in vivo. J. Immunol. 2000, 165:7164-7170.
71. Steeber D.A., Green N.E., Sato S., Tedder T.F. Lymphocyte migration in L-selectin-deficient mice. Altered subset migration and aging of the immune system. J. Immunol. 1996, 157:1096-1106.
72. Tedder T.F., Steeber D.A., Pizcueta P. L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. J. Exp. Med. 1995, 181:2259-2264.
73. Arbones M.L., Ord D.C., Ley K., Ratech H., Maynard-Curry C., Otten G., Capon D.J., Tedder T.F. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1994, 1:247-260.
74. Borsig L., Wong R., Hynes R.O., Varki N.M., Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:2193-2198.
75. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu. Rev. Immunol. 2009, 27:669-692.
76. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
77. Pucci F., Venneri M.A., Biziato D., Nonis A., Moi D., Sica A., Di Serio C., Naldini L., De Palma M. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
78. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3:23-35.
79. Schulz C., Schafer A., Stolla M., Kerstan S., Lorenz M., von Bruhl M.L., Schiemann M., Bauersachs J., Gloe T., Busch D.H., Gawaz M., Massberg S. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Circulation 2007, 116:764-773.
80. Hundhausen C., Misztela D., Berkhout T.A., Broadway N., Saftig P., Reiss K., Hartmann D., Fahrenholz F., Postina R., Matthews V., Kallen K.J., Rose-John S., Ludwig A. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003, 102:1186-1195.
81. Garton K.J., Gough P.J., Blobel C.P., Murphy G., Greaves D.R., Dempsey P.J., Raines E.W. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J. Biol. Chem. 2001, 276:37993-38001.
82. Imaizumi T., Yoshida H., Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J. Atheroscler. Thromb. 2004, 11:15-21.
83. Gevrey J.C., Isaac B.M., Cox D. Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine). J. Immunol. 2005, 175:3737-3745.
84. Ancuta P., Rao R., Moses A., Mehle A., Shaw S.K., Luscinskas F.W., Gabuzda D. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J. Exp. Med. 2003, 197:1701-1707.
85. Ancuta P., Moses A., Gabuzda D. Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology 2004, 209:11-20.
86. Ruth J.H., Volin M.V., Haines G.K., Woodruff D.C., Katschke K.J., Woods J.M., Park C.C., Morel J.C., Koch A.E. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum. 2001, 44:1568-1581.
87. Combadiere C., Potteaux S., Gao J.L., Esposito B., Casanova S., Lee E.J., Debre P., Tedgui A., Murphy P.M., Mallat Z. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003, 107:1009-1016.
88. Teupser D., Pavlides S., Tan M., Gutierrez-Ramos J.C., Kolbeck R., Breslow J.L. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:17795-17800.
89. Saederup N., Chan L., Lira S.A., Charo I.F. Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 2008, 117:1642-1648.
90. Marchesi F., Locatelli M., Solinas G., Erreni M., Allavena P., Mantovani A. Role of CX3CR1/CX3CL1 axis in primary and secondary involvement of the nervous system by cancer. J. Neuroimmunol. 2010, 224:39-44.
91. Negus R.P., Stamp G.W., Relf M.G., Burke F., Malik S.T., Bernasconi S., Allavena P., Sozzani S., Mantovani A., Balkwill F.R. The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 1995, 95:2391-2396.
92. Negus R.P., Stamp G.W., Hadley J., Balkwill F.R. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 1997, 150:1723-1734.
93. Ansari A.W., Heiken H., Meyer-Olson D., Schmidt R.E. CCL2: a potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis. Eur. J. Immunol. 2011, 41:3412-3418.
94. Leung S.Y., Wong M.P., Chung L.P., Chan A.S., Yuen S.T. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol. 1997, 93:518-527.
95. Graves D.T., Barnhill R., Galanopoulos T., Antoniades H.N. Expression of monocyte chemotactic protein-1 in human melanoma in vivo. Am. J. Pathol. 1992, 140:9-14.
96. Riethdorf L., Riethdorf S., Gutzlaff K., Prall F., Loning T. Differential expression of the monocyte chemoattractant protein-1 gene in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am. J. Pathol. 1996, 149:1469-1476.
97. Ueno T., Toi M., Saji H., Muta M., Bando H., Kuroi K., Koike M., Inadera H., Matsushima K. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 2000, 6:3282-3289.
98. Ohta M., Kitadai Y., Tanaka S., Yoshihara M., Yasui W., Mukaida N., Haruma K., Chayama K. Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int. J. Cancer 2002, 102:220-224.
99. Arenberg D.A., Keane M.P., DiGiovine B., Kunkel S.L., Strom S.R., Burdick M.D., Iannettoni M.D., Strieter R.M. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol. Immunother. 2000, 49:63-70.
100. Bottazzi B., Walter S., Govoni D., Colotta F., Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J. Immunol. 1992, 148:1280-1285.
101. Nesbit M., Schaider H., Miller T.H., Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J. Immunol. 2001, 166:6483-6490.
102. Cortez-Retamozo V., Etzrodt M., Newton A., Rauch P.J., Chudnovskiy A., Berger C., Ryan R.J., Iwamoto Y., Marinelli B., Gorbatov R., Forghani R., Novobrantseva T.I., Koteliansky V., Figueiredo J.L., Chen J.W., Anderson D.G., Nahrendorf M., Swirski F.K., Weissleder R., Pittet M.J. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2491-2496.
103. Deshmane S.L., Kremlev S., Amini S., Sawaya B.E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 2009, 29:313-326.
104. Fujimoto H., Sangai T., Ishii G., Ikehara A., Nagashima T., Miyazaki M., Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int. J. Cancer 2009, 125:1276-1284.
105. Lu Y., Cai Z., Galson D.L., Xiao G., Liu Y., George D.E., Melhem M.F., Yao Z., Zhang J. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006, 66:1311-1318.
106. Safronova O., Pluemsampant S., Nakahama K., Morita I. Regulation of chemokine gene expression by hypoxia via cooperative activation of NF-kappaB and histone deacetylase. Int. J. Biochem. Cell Biol. 2009, 41:2270-2280.
107. Negus R.P., Turner L., Burke F., Balkwill F.R. Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J. Leukoc. Biol. 1998, 63:758-765.
108. Aoi Y., Nakahama K., Morita I., Safronova O. The involvement of DNA and histone methylation in the repression of IL-1beta-induced MCP-1 production by hypoxia. Biochem. Biophys. Res. Commun. 2011, 414:252-258.
109. Li X., Kimura H., Hirota K., Sugimoto H., Yoshida H. Hypoxia reduces constitutive and TNF-alpha-induced expression of monocyte chemoattractant protein-1 in human proximal renal tubular cells. Biochem. Biophys. Res. Commun. 2005, 335:1026-1034.
110. Bosco M.C., Puppo M., Pastorino S., Mi Z., Melillo G., Massazza S., Rapisarda A., Varesio L. Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J. Immunol. 2004, 172:1681-1690.
111. White F.C., Carroll S.M., Kamps M.P. VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors 1995, 12:289-301.
112. Okunieff P., Sun J., Fenton B., Liu W., Ding I. Intratumoral VEGF and FGF1 administration alters tumor growth, vascular density, oxygenation, and expression of MCP-1 and interleukins. Adv. Exp. Med. Biol. 2007, 599:109-116.
113. Charo I.F., Myers S.J., Herman A., Franci C., Connolly A.J., Coughlin S.R. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:2752-2756.
114. Egeblad M., Ewald A.J., Askautrud H.A., Truitt M.L., Welm B.E., Bainbridge E., Peeters G., Krummel M.F., Werb Z. Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis. Model. Mech. 2008, 1:155-167. (discussion 165).
115. Lewis C., Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am. J. Pathol. 2005, 167:627-635.
116. Ziemer L.S., Koch C.J., Maity A., Magarelli D.P., Horan A.M., Evans S.M. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia 2001, 3:500-508.
117. Leek R.D., Hunt N.C., Landers R.J., Lewis C.E., Royds J.A., Harris A.L. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 2000, 190:430-436.
118. Duyndam M.C., Hilhorst M.C., Schluper H.M., Verheul H.M., van Diest P.J., Kraal G., Pinedo H.M., Boven E. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am. J. Pathol. 2002, 160:537-548.
119. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:9349-9354.
120. Li C., Liu B., Dai Z., Tao Y. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol. Ther. 2011, 12:872-880.
121. Outtz H.H., Wu J.K., Wang X., Kitajewski J. Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages. J. Immunol. 2010, 185:4363-4373.
122. Sica A., Saccani A., Bottazzi B., Bernasconi S., Allavena P., Gaetano B., Fei F., LaRosa G., Scotton C., Balkwill F., Mantovani A. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J. Immunol. 2000, 164:733-738.
123. Bosco M.C., Reffo G., Puppo M., Varesio L. Hypoxia inhibits the expression of the CCR5 chemokine receptor in macrophages. Cell. Immunol. 2004, 228:1-7.
124. Grimshaw M.J., Balkwill F.R. Inhibition of monocyte and macrophage chemotaxis by hypoxia and inflammation-a potential mechanism. Eur. J. Immunol. 2001, 31:480-489.
125. Gui T., Shimokado A., Sun Y., Akasaka T., Muragaki Y. Diverse roles of macrophages in atherosclerosis: from inflammatory biology to biomarker discovery. Mediat. Inflamm. 2012, 2012:693083.
126. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
127. Gordon S., Martinez F.O. Alternative activation of macrophages: mechanism and functions. Immunity 2010, 32:593-604.
128. Ohmori Y., Hamilton T.A. IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages. J. Immunol. 1997, 159:5474-5482.
129. Takeda K., Kamanaka M., Tanaka T., Kishimoto T., Akira S. Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J. Immunol. 1996, 157:3220-3222.
130. Cyktor J.C., Turner J. Interleukin-10 and immunity against prokaryotic and eukaryotic intracellular pathogens. Infect. Immun. 2011, 79:2964-2973.
131. Wang H.W., Joyce J.A. Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle 2010, 9:4824-4835.
132. Sato T., Terai M., Tamura Y., Alexeev V., Mastrangelo M.J., Selvan S.R. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol. Res. 2011, 51:170-182.
133. Voorzanger N., Touitou R., Garcia E., Delecluse H.J., Rousset F., Joab I., Favrot M.C., Blay J.Y. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res. 1996, 56:5499-5505.
134. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., Squadrito M.L., Segura I., Li X., Knevels E., Costa S., Vinckier S., Dresselaer T., Akerud P., De Mol M., Salomaki H., Phillipson M., Wyns S., Larsson E., Buysschaert I., Botling J., Himmelreich U., Van Ginderachter J.A., De Palma M., Dewerchin M., Claesson-Welsh L., Carmeliet P. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
135. Tugues S., Honjo S., Konig C., Noguer O., Hedlund M., Botling J., Deschoemaeker S., Wenes M., Rolny C., Jahnen-Dechent W., Mazzone M., Claesson-Welsh L. Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. Cancer Res. 2012, 72:1953-1963.
136. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166.
137. Ahn G.O., Tseng D., Liao C.H., Dorie M.J., Czechowicz A., Brown J.M. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8363-8368.